Pluri (PLUR) Stock Price, News & Analysis

Company Overview

Pluri Inc. is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company’s platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification.

Pluri’s health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow. These candidates remain subject to clinical and regulatory development and are not necessarily approved treatments.

The company has also pursued cell-based solutions outside traditional therapeutics, including cultivated food and other applications that use its cell expansion platform. Pluri is headquartered in Haifa, Israel, and its shares trade on the Nasdaq Capital Market under the symbol PLUR. The company was formerly known as Pluristem Therapeutics Inc.

Key Stats

• Today's Range: $1.20 to $1.30
• 50-Day Range: $0.85 to $1.66
• 52-Week Range: $0.85 to $4.87
• Volume: 98,937 shs
• Average Volume: 57,193 shs
• Market Capitalization: $15.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Pluri Stock Analysis - MarketRank™

Pluri scored higher than 22% of companies evaluated by MarketBeat, and ranked 817th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Pluri has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Pluri has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Pluri is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pluri is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.29% of the float of Pluri has been sold short.

Short Interest Ratio / Days to Cover

Pluri has a short interest ratio ("days to cover") of 1.79, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pluri has recently increased by 8.93%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pluri does not currently pay a dividend.

Dividend Growth

Pluri does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.67

News Sentiment

Pluri has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Pluri this week, compared to 1 article on an average week.

MarketBeat Follows

4 people have added Pluri to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.8 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $1,250,001.00 in company stock, which represents 8.2606% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Pluri insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,250,001.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

43.16% of the stock of Pluri is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

16.59% of the stock of Pluri is held by institutions.

Company Calendar

• Last Earnings: 9/10/2026
• Today: 11/02/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PLUR
• CIK: 1158780
• Web: pluri-biotech.com
• Phone: +972747107171
• Fax: 972-74-710-8787
• Employees: 92
• Year Founded: 2001

Profitability

• EPS (Trailing Twelve Months): ($2.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.82 million
• Net Margins: -2,344.59%
• Pretax Margin: -2,499.41%
• Return on Equity: N/A
• Return on Assets: -82.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.27
• Quick Ratio: 0.27

Sales & Book Value

• Annual Sales: $1.02 million
• Price / Sales: 14.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.62) per share
• Price / Book: -0.74

Miscellaneous

• Outstanding Shares: 12,610,000
• Free Float: 7,168,000
• Market Cap: $15.13 million
• Optionable: No Data
• Beta: 0.69